patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_652584 | REC_0002801 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 13.6 | 68 | female | 0 | 18 | 5.6 | 8 | pembrolizumab 200 mg q3w | 12.2 | true | MSI-H | 2026-03-15T05:35:57.535153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496363 | REC_0002802 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.9 | 65 | female | 1 | 30 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.3 | true | MSS | 2026-03-15T05:35:57.535382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533911 | REC_0002803 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 14.7 | 68 | female | 0 | 17 | 4.9 | 7 | entrectinib 600 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:57.535614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_240968 | REC_0002804 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 11.7 | 71 | female | 2 | 9 | 5.5 | 1 | sotorasib 960 mg daily | 12 | false | MSS | 2026-03-15T05:35:57.535848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_509417 | REC_0002805 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 7.3 | 70 | female | 0 | 19 | 6.7 | 4 | osimertinib 80 mg daily | 9.4 | true | MSS | 2026-03-15T05:35:57.536153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649567 | REC_0002806 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 26 | 14.1 | 75 | female | 1 | 13 | 5.9 | 0 | alectinib 600 mg BID | 45.6 | true | MSS | 2026-03-15T05:35:57.536402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273411 | REC_0002807 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 5.8 | 70 | female | 0 | 56 | 5.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:35:57.536634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710862 | REC_0002808 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 7.6 | 59 | female | 0 | 12 | 6.3 | 6 | sotorasib 960 mg daily | 15.6 | false | MSS | 2026-03-15T05:35:57.536867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210478 | REC_0002809 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 13.9 | 80 | female | 1 | 16 | 7.2 | 2 | sotorasib 960 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.537149+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207847 | REC_0002810 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 12 | 69 | male | 1 | 13 | 4.6 | 7 | alectinib 600 mg BID | 9.6 | false | MSI-H | 2026-03-15T05:35:57.537386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620879 | REC_0002811 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 16.6 | 49 | female | 0 | 14 | 4.8 | 2 | osimertinib 80 mg daily | 34 | true | MSS | 2026-03-15T05:35:57.537623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256287 | REC_0002812 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 14 | 70 | female | 2 | 24 | 5.2 | 9 | entrectinib 600 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:35:57.537853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598373 | REC_0002813 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 9.7 | 80 | female | 1 | 18 | 6 | 0 | alectinib 600 mg BID | 21.1 | true | MSS | 2026-03-15T05:35:57.538080+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312922 | REC_0002814 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 13.9 | 74 | male | 1 | 24 | 5.9 | 2 | entrectinib 600 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:57.538314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377585 | REC_0002815 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3 | 69 | female | 0 | 46 | 6 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:35:57.538551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363840 | REC_0002816 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 12.1 | 69 | male | 1 | 11 | 5 | 1 | alectinib 600 mg BID | 14.6 | false | MSI-H | 2026-03-15T05:35:57.538797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941473 | REC_0002817 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 11.5 | 59 | female | 0 | 14 | 7 | 1 | osimertinib 80 mg daily | 18.6 | true | MSS | 2026-03-15T05:35:57.539057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691540 | REC_0002818 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 6.1 | 68 | female | 1 | 17 | 6.6 | 7 | pembrolizumab 200 mg q3w | 8.4 | true | MSS | 2026-03-15T05:35:57.539307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775673 | REC_0002819 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.6 | 70 | female | 2 | 32 | 7.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.4 | true | MSS | 2026-03-15T05:35:57.539556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402314 | REC_0002820 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 15.1 | 68 | female | 1 | 17 | 4 | 5 | osimertinib 80 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:57.539801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547381 | REC_0002821 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 13.5 | 71 | female | 1 | 8 | 5.8 | 2 | alectinib 600 mg BID | 18.5 | true | MSI-H | 2026-03-15T05:35:57.540032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475224 | REC_0002822 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 11 | 65 | female | 0 | 19 | 3.9 | 2 | osimertinib 80 mg daily | 15 | true | MSS | 2026-03-15T05:35:57.540418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909390 | REC_0002823 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 9.2 | 75 | female | 2 | 20 | 5.3 | 3 | sotorasib 960 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:57.540661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334293 | REC_0002824 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 26 | 13.2 | 61 | male | 1 | 15 | 4.4 | 0 | entrectinib 600 mg daily | 32.9 | true | MSI-H | 2026-03-15T05:35:57.540900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584327 | REC_0002825 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5.4 | 58 | male | 0 | 27 | 4.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.8 | true | MSS | 2026-03-15T05:35:57.541132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502891 | REC_0002826 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 15.6 | 84 | female | 2 | 6 | 5.9 | 5 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:35:57.541367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288363 | REC_0002827 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 12.3 | 76 | female | 1 | 14 | 5.3 | 6 | osimertinib 80 mg daily | 10.6 | false | MSI-H | 2026-03-15T05:35:57.541604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128674 | REC_0002828 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 15 | 11.1 | 58 | female | 1 | 10 | 4.5 | 2 | alectinib 600 mg BID | 20.8 | true | MSS | 2026-03-15T05:35:57.541837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_163417 | REC_0002829 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 16.3 | 56 | female | 1 | 22 | 6.1 | 7 | alectinib 600 mg BID | 11.7 | true | MSS | 2026-03-15T05:35:57.542071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649299 | REC_0002830 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 5.9 | 62 | female | 1 | 24 | 6.3 | 7 | alectinib 600 mg BID | 6.4 | true | MSS | 2026-03-15T05:35:57.542302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918542 | REC_0002831 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 28 | 12 | 75 | male | 2 | 16 | 7 | 0 | entrectinib 600 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:57.542538+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635537 | REC_0002832 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 8.6 | 69 | female | 1 | 16 | 6 | 6 | sotorasib 960 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:57.542763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971627 | REC_0002833 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 11.3 | 77 | female | 1 | 18 | 6.2 | 1 | entrectinib 600 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:57.542993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950628 | REC_0002834 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 14.3 | 65 | female | 1 | 17 | 6.7 | 7 | alectinib 600 mg BID | 17.7 | true | MSS | 2026-03-15T05:35:57.543231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755065 | REC_0002835 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 7.1 | 67 | male | 0 | 17 | 7.9 | 2 | pembrolizumab 200 mg q3w | 6.5 | false | MSS | 2026-03-15T05:35:57.543539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617677 | REC_0002836 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.5 | 67 | female | 1 | 15 | 3 | 8 | pembrolizumab 200 mg q3w | 10.2 | false | MSS | 2026-03-15T05:35:57.543772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116366 | REC_0002837 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5.2 | 67 | female | 1 | 49 | 6 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.6 | true | MSS | 2026-03-15T05:35:57.544003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476762 | REC_0002838 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 12.9 | 69 | female | 0 | 17 | 5.7 | 2 | sotorasib 960 mg daily | 24.9 | false | MSI-H | 2026-03-15T05:35:57.544301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894818 | REC_0002839 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.4 | 51 | female | 0 | 11 | 5.8 | 3 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:57.544541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885270 | REC_0002840 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.6 | 47 | female | 0 | 7 | 5.8 | 4 | entrectinib 600 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:35:57.544776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287640 | REC_0002841 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 11.2 | 67 | female | 0 | 17 | 4.7 | 5 | entrectinib 600 mg daily | 8.4 | true | MSS | 2026-03-15T05:35:57.545012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609671 | REC_0002842 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 7.7 | 72 | female | 2 | 21 | 7.6 | 2 | alectinib 600 mg BID | 15.7 | true | MSS | 2026-03-15T05:35:57.545243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722311 | REC_0002843 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 11.3 | 77 | female | 1 | 18 | 5.6 | 2 | sotorasib 960 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:35:57.545473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560614 | REC_0002844 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 34 | 7.2 | 74 | female | 1 | 17 | 2.1 | 2 | osimertinib 80 mg daily | 27.9 | false | MSS | 2026-03-15T05:35:57.545702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486733 | REC_0002845 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 15.2 | 76 | female | 2 | 14 | 3.5 | 2 | alectinib 600 mg BID | 15.6 | false | MSS | 2026-03-15T05:35:57.545939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986838 | REC_0002846 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 9.7 | 82 | female | 2 | 4 | 3.7 | 1 | osimertinib 80 mg daily | 21.8 | false | MSS | 2026-03-15T05:35:57.546167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800902 | REC_0002847 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 10.6 | 60 | male | 0 | 13 | 3.1 | 6 | sotorasib 960 mg daily | 11.3 | true | MSI-H | 2026-03-15T05:35:57.546402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483475 | REC_0002848 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 11.1 | 70 | female | 1 | 17 | 4.9 | 2 | osimertinib 80 mg daily | 7 | false | MSS | 2026-03-15T05:35:57.546684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533260 | REC_0002849 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 11.3 | 69 | male | 1 | 20 | 6.2 | 8 | entrectinib 600 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:57.546922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606936 | REC_0002850 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 11.5 | 75 | female | 1 | 25 | 7.6 | 9 | alectinib 600 mg BID | 19.8 | false | MSI-H | 2026-03-15T05:35:57.547154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622007 | REC_0002851 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 14.7 | 62 | female | 1 | 30 | 3.6 | 1 | entrectinib 600 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:57.547392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528365 | REC_0002852 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 13.9 | 51 | male | 0 | 14 | 5.5 | 7 | entrectinib 600 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:57.547627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165238 | REC_0002853 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 3.5 | 82 | female | 1 | 29 | 5.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.2 | false | MSS | 2026-03-15T05:35:57.547855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971722 | REC_0002854 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 6.8 | 65 | female | 1 | 16 | 5.8 | 8 | pembrolizumab 200 mg q3w | 10.4 | false | MSS | 2026-03-15T05:35:57.548124+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928832 | REC_0002855 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.6 | 66 | female | 1 | 22 | 4.8 | 7 | pembrolizumab 200 mg q3w | 11.8 | true | MSS | 2026-03-15T05:35:57.548367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885050 | REC_0002856 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 33 | 3 | 59 | female | 1 | 39 | 5.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.3 | false | MSS | 2026-03-15T05:35:57.548601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529802 | REC_0002857 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 13 | 14.6 | 75 | female | 1 | 15 | 5.5 | 10 | entrectinib 600 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:35:57.548835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575012 | REC_0002858 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 12.2 | 77 | male | 2 | 13 | 5.8 | 1 | osimertinib 80 mg daily | 16.5 | false | MSI-H | 2026-03-15T05:35:57.549071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147948 | REC_0002859 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 12.6 | 77 | female | 0 | 7 | 4.7 | 5 | entrectinib 600 mg daily | 4.6 | false | MSI-H | 2026-03-15T05:35:57.549303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_261471 | REC_0002860 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 13.1 | 88 | female | 1 | 17 | 4.5 | 7 | alectinib 600 mg BID | 11.2 | false | MSS | 2026-03-15T05:35:57.549534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917167 | REC_0002861 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 11.3 | 85 | female | 2 | 13 | 6.5 | 1 | osimertinib 80 mg daily | 25.2 | false | MSS | 2026-03-15T05:35:57.549812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971948 | REC_0002862 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 4.1 | 66 | female | 1 | 26 | 5.2 | 7 | pembrolizumab 200 mg q3w | 17.3 | false | MSS | 2026-03-15T05:35:57.550050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570704 | REC_0002863 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 15.4 | 60 | female | 1 | 11 | 5.4 | 4 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:35:57.550289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551283 | REC_0002864 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 4.9 | 69 | female | 0 | 36 | 4.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 7.7 | true | MSS | 2026-03-15T05:35:57.550516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267483 | REC_0002865 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 16 | 3.1 | 71 | male | 1 | 14 | 4.6 | 5 | pembrolizumab 200 mg q3w | 9.5 | true | MSS | 2026-03-15T05:35:57.550747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974114 | REC_0002866 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 16.8 | 63 | male | 0 | 12 | 4.5 | 1 | alectinib 600 mg BID | 18.1 | false | MSI-H | 2026-03-15T05:35:57.550983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714611 | REC_0002867 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 7.8 | 63 | male | 1 | 18 | 3.6 | 6 | sotorasib 960 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:57.551216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601719 | REC_0002868 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 16.3 | 75 | female | 2 | 18 | 6 | 5 | osimertinib 80 mg daily | 17.4 | false | MSS | 2026-03-15T05:35:57.551445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_674647 | REC_0002869 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.8 | 69 | female | 0 | 38 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.8 | false | MSS | 2026-03-15T05:35:57.551674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374120 | REC_0002870 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11 | 67 | female | 1 | 16 | 5.4 | 6 | entrectinib 600 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:57.551906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165691 | REC_0002871 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 10.9 | 74 | female | 1 | 20 | 6.1 | 8 | pembrolizumab 200 mg q3w | 8.1 | false | MSS | 2026-03-15T05:35:57.552164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430190 | REC_0002872 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 7.6 | 68 | female | 1 | 12 | 6.3 | 6 | entrectinib 600 mg daily | 5.8 | true | MSS | 2026-03-15T05:35:57.552397+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_261826 | REC_0002873 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 8.7 | 70 | male | 1 | 5 | 4.7 | 7 | osimertinib 80 mg daily | 10.9 | true | MSS | 2026-03-15T05:35:57.552631+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354385 | REC_0002874 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 34 | 14.1 | 55 | male | 0 | 26 | 7 | 2 | osimertinib 80 mg daily | 29.7 | true | MSS | 2026-03-15T05:35:57.552911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205245 | REC_0002875 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 9.4 | 74 | female | 2 | 13 | 6.6 | 5 | entrectinib 600 mg daily | 6.7 | true | MSS | 2026-03-15T05:35:57.553144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535935 | REC_0002876 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 31 | 11 | 63 | female | 0 | 16 | 5.4 | 0 | osimertinib 80 mg daily | 33.5 | true | MSS | 2026-03-15T05:35:57.553382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836352 | REC_0002877 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 17.1 | 61 | male | 1 | 12 | 8.1 | 10 | osimertinib 80 mg daily | 4.4 | false | MSS | 2026-03-15T05:35:57.553617+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125456 | REC_0002878 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 15.6 | 62 | female | 1 | 15 | 4.1 | 5 | sotorasib 960 mg daily | 6 | false | MSS | 2026-03-15T05:35:57.553850+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799859 | REC_0002879 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 2.5 | 63 | male | 0 | 22 | 6.3 | 5 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:57.554083+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989450 | REC_0002880 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 7.3 | 67 | female | 1 | 38 | 4.8 | 2 | pembrolizumab 200 mg q3w | 24.9 | true | MSS | 2026-03-15T05:35:57.554311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278717 | REC_0002881 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 17.1 | 75 | female | 1 | 13 | 6 | 1 | entrectinib 600 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:57.554543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717628 | REC_0002882 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 13 | 77 | female | 1 | 11 | 5.8 | 2 | osimertinib 80 mg daily | 23 | true | MSS | 2026-03-15T05:35:57.554772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980526 | REC_0002883 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 6.2 | 58 | female | 1 | 56 | 6.4 | 1 | pembrolizumab 200 mg q3w | 5.8 | true | MSS | 2026-03-15T05:35:57.555004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931943 | REC_0002884 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 20 | 7.6 | 70 | male | 1 | 4 | 4.7 | 0 | osimertinib 80 mg daily | 33.2 | true | MSS | 2026-03-15T05:35:57.555235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569049 | REC_0002885 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 10.2 | 68 | male | 1 | 10 | 5.5 | 6 | sotorasib 960 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:57.555469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161662 | REC_0002886 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 5 | 56 | male | 1 | 4 | 5.9 | 1 | alectinib 600 mg BID | 25.3 | true | MSS | 2026-03-15T05:35:57.555701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962745 | REC_0002887 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 13 | 8.7 | 57 | male | 0 | 4 | 4.3 | 3 | sotorasib 960 mg daily | 21.7 | true | MSS | 2026-03-15T05:35:57.555972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670289 | REC_0002888 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 18.1 | 80 | male | 2 | 14 | 7.4 | 3 | osimertinib 80 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:57.556306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752558 | REC_0002889 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 10.5 | 69 | female | 0 | 21 | 4.8 | 4 | osimertinib 80 mg daily | 8.4 | true | MSI-H | 2026-03-15T05:35:57.556546+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556947 | REC_0002890 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 13.2 | 61 | male | 0 | 27 | 4.1 | 1 | osimertinib 80 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:57.556783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390805 | REC_0002891 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 9.6 | 73 | female | 0 | 16 | 5.7 | 2 | sotorasib 960 mg daily | 18.1 | false | MSS | 2026-03-15T05:35:57.557015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519403 | REC_0002892 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.5 | 76 | female | 2 | 1 | 6.8 | 4 | alectinib 600 mg BID | 13.2 | true | MSS | 2026-03-15T05:35:57.557253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128220 | REC_0002893 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 8.1 | 61 | male | 1 | 14 | 4.8 | 1 | alectinib 600 mg BID | 20.1 | false | MSS | 2026-03-15T05:35:57.557485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763821 | REC_0002894 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.8 | 63 | male | 0 | 32 | 6 | 9 | carboplatin + paclitaxel + pembrolizumab | 12.8 | true | MSS | 2026-03-15T05:35:57.557718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330333 | REC_0002895 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 8.9 | 70 | female | 1 | 20 | 5 | 7 | sotorasib 960 mg daily | 20.2 | true | MSS | 2026-03-15T05:35:57.557946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318709 | REC_0002896 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.1 | 67 | female | 0 | 44 | 7.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.8 | false | MSS | 2026-03-15T05:35:57.558177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585057 | REC_0002897 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 3.8 | 77 | female | 1 | 58 | 6.5 | 8 | carboplatin + paclitaxel + pembrolizumab | 12.6 | true | MSS | 2026-03-15T05:35:57.558405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976145 | REC_0002898 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 15 | 4.3 | 66 | female | 0 | 16 | 5.4 | 1 | alectinib 600 mg BID | 21.2 | true | MSS | 2026-03-15T05:35:57.558637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_793816 | REC_0002899 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.7 | 63 | female | 0 | 8 | 5.5 | 8 | entrectinib 600 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:57.558892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162703 | REC_0002900 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 9.2 | 70 | female | 2 | 20 | 3.7 | 4 | osimertinib 80 mg daily | 6.2 | false | MSS | 2026-03-15T05:35:57.559229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.